Haven Private LLC Takes $286,000 Position in Novartis AG (NYSE:NVS)

Haven Private LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,939 shares of the company’s stock, valued at approximately $286,000.

Other institutional investors have also recently made changes to their positions in the company. Human Investing LLC purchased a new stake in Novartis during the 4th quarter worth about $25,000. Union Bancaire Privee UBP SA purchased a new stake in Novartis during the 4th quarter worth about $27,000. Legacy Investment Solutions LLC purchased a new stake in Novartis during the 3rd quarter worth about $28,000. Kestra Investment Management LLC purchased a new stake in Novartis during the 4th quarter worth about $47,000. Finally, Brooklyn Investment Group purchased a new stake in Novartis during the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Analysts Set New Price Targets

NVS has been the topic of several research analyst reports. Erste Group Bank restated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Finally, Morgan Stanley assumed coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an “underweight” rating for the company. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Novartis presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Up 1.0 %

NYSE:NVS opened at $113.00 on Friday. The firm has a market cap of $230.97 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.70 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The firm has a 50-day simple moving average of $103.67 and a two-hundred day simple moving average of $108.02.

Novartis (NYSE:NVS) last released its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.